Colgate-Palmolive (CL)

The sleeper story isn't the beat-and-raise, it's that the U.S. turnaround clock just got reset: last quarter's 'second half actions' have quietly become a 2027 portfolio payoff , and free cash flow growth decelerated from 18% to 7% YTD with no question asked about it . The obvious headline, 'gross margin guidance raised again,' is really a story about Funding the Growth and SGPP productivity (+290bps and a program that runs through 2028 ) offsetting a cost environment management itself calls 'stubborn' , not demand strength. The binding constraint here isn't volume, it's cost visibility into 2027: commodities are 'largely locked in for Q4' but management explicitly flagged commodity volatility as 'a headwind heading into 2027' while simultaneously retiring the private label metric that's been flattering their volume comps. Noel's own words say it best: 'this is very much a work in process... you're going to start to see that translate into a better portfolio in 2027' , that's a credibility marker, not a victory lap. My view changes if next quarter management (1) quantifies the SGPP vs. underlying productivity split in SG&A, and (2) explains the FCF deceleration with a working-capital or capex driver rather than silence.